Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Fluorodeoxyglucose F 18
48%
Positron Emission Tomography
35%
Neoplasm
33%
Disease
31%
Single-Photon Emission Computed Tomography
30%
Computer Assisted Tomography
27%
Positron Emission Tomography
25%
Fluorine-18
24%
Technetium-99
23%
Gallium 68
22%
Scintigraphy
22%
Prostate Cancer
19%
Metastatic Carcinoma
16%
Cancer
16%
Prostate Specific Membrane Antigen
13%
Single Photon Emission Computed Tomography-Computed Tomography
13%
Bone Scintigraphy
12%
Fluorodeoxyglucose
12%
Bone Metastasis
12%
Biopsy
11%
Radioactive Tracer
11%
Breast Cancer
11%
Sentinel Node
10%
Diagnostic Accuracy
10%
Gallium 67
10%
Diagnosis
10%
Recurrent Disease
10%
Nodular Melanoma
9%
Malignant Neoplasm
9%
Gamma Camera
9%
Leukocyte
8%
Indium 111
7%
Primary Tumor
7%
Bone Disease
7%
Lymph Node
7%
Standardized Uptake Value
6%
Lymphoscintigraphy
5%
Nuclear Medicine
5%
Anatomy
5%
Lymphadenopathy
5%
Hybrid Imaging
5%
Tomography
5%
Morphology
5%
Sentinel-Node Mapping
5%
Medronic Acid
5%
Pelvis
5%
Keyphrases
Positron Emission Tomography-computed Tomography (PET-CT)
92%
Single-photon Emission Computed Tomography (SPECT)
40%
Lymphoma
24%
Tumor
21%
18F-fluorodeoxyglucose (18F-FDG)
21%
18F-FDG PET-CT
20%
Positron Emission Tomography
17%
Computed Tomography
16%
Bleomycin
13%
Prostate-specific Antigen
13%
Parkinson's Disease
13%
Prostate Cancer
12%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
12%
Bone Metastasis
12%
Bone Involvement
11%
Sentinel Lymph Node Mapping
11%
Technetium-99m
10%
Diagnostic Accuracy
10%
Non-Hodgkin Lymphoma
10%
Fluorodeoxyglucose
9%
Metastasis
9%
SPECT-CT
9%
Scintigraphy
9%
Gallium-68
9%
CT Findings
9%
Bone Scintigraphy
9%
CT Studies
9%
18F-fluoride PET
9%
Malignancy
8%
CT System
8%
Ga-67
8%
Cobalt-57
8%
Gamma Camera
8%
Negative Predictive Value
8%
Computerized Tomography
8%
18F-fluoride
7%
Positive Predictive Value
7%
Sentinel Lymph Node
7%
Melanoma
7%
High-grade Prostate Cancer
7%
Leucine-rich Repeat Kinase 2 (LRRK2)
7%
Imaging Modalities
7%
Standardized Uptake Value
7%
FDG Uptake
7%
Hybrid Imaging
6%
Primary Tumor
6%
Computed Tomographic
6%
Prostate Cancer Patients
6%
Lymphoscintigraphy
6%
Metastatic Melanoma
6%